Sen-Jam Pharmaceutical has a total of 40 patents globally, out of which 10 have been granted. Of these 40 patents, more than 70% patents are active. The United States of America is where Sen-Jam Pharmaceutical has filed the maximum number of patents, followed by Europe (EPO) and Australia. Parallelly, The United States of America seems to be the main focused R&D center and also origin country of Sen-Jam Pharmaceutical.
Sen-Jam Pharmaceutical was founded in the year 2014. Sen-Jam Pharmaceutical is a medical company that uses the development pathway to create innovative pharmaceutical solutions for significant unmet needs.
Do read about some of the most popular patents of Sen-Jam Pharmaceutical which have been covered by us in this article and also you can find Sen-Jam Pharmaceutical patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Sen-Jam Pharmaceutical patent portfolio.
How many patents does Sen-Jam Pharmaceutical have?
Sen-Jam Pharmaceutical has a total of 40 patents globally. These patents belong to 9 unique patent families. Out of 40 patents, 28 patents are active.
How Many Patents did Sen-Jam Pharmaceutical File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Sen-Jam Pharmaceutical Applications Filed | Sen-Jam Pharmaceutical Patents Granted |
| 2023 | 3 | 1 |
| 2022 | 2 | 5 |
| 2021 | 8 | 1 |
| 2020 | 2 | 2 |
| 2019 | 3 | 1 |
| 2018 | 15 | – |
| 2016 | 7 | – |
How many Sen-Jam Pharmaceutical patents are Alive/Dead?
Worldwide Patents
How Many Patents did Sen-Jam Pharmaceutical File in Different Countries?
Countries in which Sen-Jam Pharmaceutical Filed Patents
| Country | Patent |
| United States Of America | 13 |
| Europe | 5 |
| Australia | 3 |
| Canada | 2 |
| Mexico | 1 |
| Poland | 1 |
| New Zealand | 1 |
| Brazil | 1 |
| Austria | 1 |
| Singapore | 1 |
| Spain | 1 |
| South Africa | 1 |
| Israel | 1 |
| Italy | 1 |
Where are Research Centers of Sen-Jam Pharmaceutical Patents Located?
What Percentage of Sen-Jam Pharmaceutical US Patent Applications were Granted?
Sen-Jam Pharmaceutical (Excluding its subsidiaries) has filed 9 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 6 have been granted leading to a grant rate of 75%.
Below are the key stats of Sen-Jam Pharmaceutical patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Sen-Jam Pharmaceutical?
| Law Firm | Total Applications | Success Rate |
| Morgan Lewis & Bockius Llp Bo | 9 | 75.0% |
List of Sen-Jam Pharmaceutical patents
| Sen-Jam Pharmaceutical Patents | Title |
| US11464766B2 | Methods And Compositions To Inhibit Symptoms Associated With Veisalgia |
| US11129803B2 | Methods And Compositions To Inhibit Tolerance To Opioids |
| US10765630B2 | Methods And Compositions To Treat Enteropathic Arthritis |
| US10675261B2 | Methods And Compositions To Inhibit Dependence On Opioids |
| US10420756B2 | Methods And Compositions To Inhibit Symptoms Associated With Veisalgia |
| US20230064685A1 | Methods And Compositions To Inhibit Symptoms Associated With Veisalgia |
| US20220265585A1 | Methods And Compositions To Inhibit Symptoms Associated With Opioid Withdrawal |
| US20220096409A1 | Methods And Compositions To Inhibit Tolerance To Opioids |
| US20210212971A1 | Methods And Compositions To Inhibit Dependence On Opioids |
| US20200297707A1 | Methods And Compositions To Inhibit Symptoms Associated With Viral Upper Respiratory Tract Infections |
| EP3273952B1 | Combination Of Naproxen And Fexofenadine To Inhibit Symptoms Associated With Veisalgia |
| EP4192457A1 | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| EP3973957A1 | Methods And Compositions To Inhibit Symptoms Associated With Veisalgia |
| AU2018333954B2 | Methods And Compositions To Inhibit Dependence On Opioids |
| AU2021321535A1 | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| AU2018333952A1 | Methods And Compositions To Inhibit Symptoms Associated With Opioid Withdrawal |
| CA3076197A1 | Methods And Compositions To Inhibit Dependence On Opioids |
| CA3076193A1 | Methods And Compositions To Inhibit Symptoms Associated With Opioid Withdrawal |
| IL300406A | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| SG11202300846SA | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| BR112023002233A2 | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| PL3273952T3 | Combination Of Naproxen And Fexofenadine To Inhibit Symptoms Associated With Veisalgia |
| ES2926494T3 | Combination Of Naproxen And Fexofenadine To Inhibit Symptoms Associated With Veisalgia |
| IT202200057570T2 | Combination Of Naproxene And Phexofenadine To Inhibit Symptoms Associated With Veisalgia |
| MX2023001570A | Compositions And Methods For Treating Or Preventing A Disease Associated With Betacoronavirus Infection |
| ZA202303234A | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| AT1497959T | Kombination Von Naproxen Und Fexofenadine Zur Hemmung Von Symptomen Im Zusammenhang Mit Veisalgia |
| NZ797537A | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| US20200297673A1 | Methods And Compositions To Inhibit Dependence On Opioids |
| US20190083430A1 | Methods And Compositions To Inhibit Symptoms Associated With Opioid Withdrawal |
| US20180360811A1 | Methods And Compositions To Inhibit Symptoms Associated With Viral Upper Respiratory Tract Infections |
| EP3684360A4 | Methods And Compositions To Inhibit Dependence On Opioids |
| EP3684347A4 | Methods And Compositions To Inhibit Symptoms Associated With Opioid Withdrawal |
| WO2022032069A1 | Compositions And Methods For Treating Or Preventing Disease Associated With Beta Coronavirus Infection |
| WO2019178516A1 | Methods And Compositions To Treat Enteropathic Arthritis |
| WO2019055942A4 | Methods And Compositions To Inhibit Tolerance To Opioids |
| WO2019055941A1 | Methods And Compositions To Inhibit Dependence On Opioids |
| WO2019055939A1 | Methods And Compositions To Inhibit Symptoms Associated With Opioid Withdrawal |
| WO2019046201A1 | Methods And Compositions To Inhibit Adverse Effects Associated With Vaccinations |
| WO2018232260A1 | Methods And Compositions To Inhibit Symptoms Associated With Viral Upper Respiratory Tract Infections |
What are Sen-Jam Pharmaceutical key innovation segments?
What Technologies are Covered by Sen-Jam Pharmaceutical?
The chart below distributes patents filed by Sen-Jam Pharmaceutical